Purpose: estimate efficiency minimally invasive methods of treatment at patients with tumor lesion of bones.

Materials and methods: 145 patients, middle age e 42 years. it has been executed 249 percutaneous vertebroplasty, 15 osteoplasty and 46 radiofrequency thermal ablation Most often minimally invasive methods were carried out to patients with bone metastasis lesion of a breast cancer – 65 (44,8%) and kidneys – 14 (10%) patients.

Results: reduction in a painful syndrome on a visual analog scale after operation is noted at 126 (87%) by patients. Positive dynamics Watkins scale at 119 (82%). Improvement of quality of a life on scale Karnofski at 94 (65%) the patient. Complications after vertebroplasty and osteoplasty in the form of methylmethacrylate leak into the surrounding tissues at 19 (18,5%) patients. At one patient after radiofrequency thermal ablation has developed burn skin. There were three pathological bone fractures after radiofrequency thermal ablation.

Conclusions: vertebroplasty, osteoplasty and radiofrequency thermal ablation – minimally invasive methods of treatment the patients with tumoral lesion of the bones, allowing in short tim stop a painful syndrome, create adequate stability in a bone segment and improve quality of a life of oncological patients.

The aim of the study was to examine TRAP-5b as serum tumor marker for patients with primary malignant bone tumors.

In total 69 patients were included in protocol: 34 – with primary malignant bone tumors – 1st group, 35 – with non-oncologic pathology of bone tissue (12 – with benign bone tumors and 23 – with traumatic bone fractures) – 2nd group and 38 healthy donors – 3rd group. The distribution of patients according age and sex in all groups was similar. The level of TRAP-5b was examined by means of immunoassay method.

The low value (< 3,0 U/L) of TRAP-5b was found in 39% cases in 2nd group, in 31% cases of donors in 3rd group and only in 3% cases of patients with malignant bone tumors. High concentrations of TRAP-5b (> 6,0 U/L) were found in serum of only one patient from 2nd group and only one donor. At the same time TRAP-5b level more than 6,0 U/L was determined in 35% cases of patients with malignancies. The average TRAP-5b value was: 6,14±0,51 U/L in 1st group, 3,9±0,18 U/L in 2nd and 3,7±0,27 U/L in 3rd group. The marker level was higher in group of patients with osteolytic component of bone destruction, compared with group of patients with mixed type of destruction (7,74±0,73 U/L vs. 4,48±0,92 U/L).